Secure your place at the Digiday Media Buying Summit in Nashville, March 2-4
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Digiday+ Research: Brand marketing will be the priority in 2026, after revenues fell short of expectations
Revenues fell short of marketers’ expectations in 2025. But they’ll be working with bigger budgets in 2026, and focusing on brand marketing.
ChatGPT enters the ad game. Now what?
OpenAI has begun testing ads in ChatGPT through premium brand partnerships, signaling a new phase in its monetization strategy.
Ad Tech Briefing: A mid-term report card
Despite earnings increases, stock prices are down demonstrating how the public markets are a cruel place.